(Q35129027)

6 August 2017

title

Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor (English)

1 reference

6 August 2017

1 reference

Melody R Vander Straten

series ordinal

1

1 reference

6 August 2017

Mohammad A Hossain

series ordinal

2

1 reference

6 August 2017

Mahmoud A Ghannoum

series ordinal

3

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Infectious Disease Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

87-112

1 reference

Superficial fungal infection of the skin. Where and how it appears help determine therapy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

New developments in chemotherapy for non-invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Oral griseofulvin remains the treatment of choice for tinea capitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Tinea capitis: a current perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Tinea manus treated with 1-week itraconazole vs. terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Current Management of Onychomycosis and Dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Terbinafine. An update of its use in superficial mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Fluconazole in the treatment of tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Treatment of tinea capitis: beyond griseofulvin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. The Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Fungal infections in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Resistance of Candida species to antifungal agents used in the treatment of onychomycosis: a review of current problems

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Onychomycosis treated until the nail is replaced by normal growth or there is failure

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Oral therapy of common superficial fungal infections of the skin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Adverse drug reactions of the new oral antifungal agents--terbinafine, fluconazole, and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Antifungal drug interactions. Avoidance requires more than memorization

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Possible drug interactions in oral treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

Systemic antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900065-X

7 January 2021

10.1016/S0891-5520(02)00065-X

Identifiers

DOI

1 reference

6 August 2017

1 reference